We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the CORONAVIRUS EPIDEMIC, certain events are being rescheduled for a later date or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
14 Apr 2020 - 17 Apr 2020
16 Apr 2020 - 17 Apr 2020

Helicobacter pylori Triggers Development of Stomach Disease

By LabMedica International staff writers
Posted on 23 Jan 2020
Print article
Image: Immunostaining of Helicobacter pylori infection in a gastric foveolar pit demonstrated in endoscopic gastric biopsy (Photo courtesy of KGH).
Image: Immunostaining of Helicobacter pylori infection in a gastric foveolar pit demonstrated in endoscopic gastric biopsy (Photo courtesy of KGH).
Helicobacter pylori is a paradigm persistent pathogen colonizing about 50% of the human world population and represents a major risk factor for chronic gastritis, peptic ulceration and gastric malignancies.

Toll-like receptor TLR5 recognizes a conserved domain, termed D, that is present in flagellins of several pathogenic bacteria, but not in Helicobacter pylori. Highly virulent H. pylori strains possess a type IV secretion system (T4SS) for delivery of virulence factors into gastric epithelial cells.

Microbiologists at the Friedrich Alexander University Erlangen-Nuremberg (Erlangen, Germany) and their colleagues investigated how the H. pylori manipulate the host's immune system in order to ensure their long-term survival in the stomach. A chronic inflammation is the most common cause for stomach illnesses. The team has identified a 'molecular switch' which uses a previously unknown mechanism to regulate the inflammation reaction in the stomach.

The interaction between H. pylori and stomach cells activates a syringe-like pilus structure referred to as a type IV secretion system. A protein, CagL, is presented at the surface of this structure which allows the bacterial toxin known as CagA protein to be delivered into the stomach cells. The injected CagA then re-programmes the host cell so that stomach cancer can develop. However, it now appears that CagL also has another important function. The protein is recognized by the immune system via the receptor TLR5. CagL imitates a TLR5 recognition motif in the flagellin protein of other pathogens, thereby controlling the human immune response.

Interestingly, this signaling pathway can be both switched on and switched off by the type IV secretion system, which is not thought to be the case with other bacteria. Presumably, H. pylori has exploited this signalling pathway over thousands of years of evolution to eliminate 'bothersome' bacterial competitors in the stomach. At the same time, CagL influences the congenital and adaptive immune system as well as the inflammation reaction in such a way that H. pylori itself is not recognized and therefore cannot be eliminated, a mechanism which is crucial for long-term infections with H. pylori in the stomach and triggering stomach disease.

The team also observed that TLR5 is no longer produced in healthy stomach cells and once an infection has been resolved. This indicates that the expression of this protein is a new indicator for stomach disease in humans triggered by H. pylori. The study was published on December 16, 2019 in the journal Nature Communications.

Related Links:
Friedrich Alexander University Erlangen-Nuremberg


Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.